ANIXAnixa BiosciencesANIX info
$3.40info3.03%24h
Global rank20947
Market cap$105.64M
Change 7d6.25%
YTD Performance-12.82%
SP500 benchmarkUnderperform
P/E0
P/S503.04
Revenue$210.00K
Earnings-$9.93M
Dividend yield-
Main Sector
Healthcare

Anixa Biosciences (ANIX) Stock Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ANIX Stock Information

Symbol
ANIX
Address
3150 Almaden ExpresswaySan Jose, CA 95118United States
Founded
-
Trading hours
-
Website
https://www.anixa.com
Country
πŸ‡ΊπŸ‡Έ United States
Phone Number
408 708 9808

Anixa Biosciences (ANIX) Price Chart

-
Value:-

Anixa Biosciences Overview: Key Details and Summary

Stock data
2023
Change
Price
$3.40
N/A
Market Cap
$105.64M
N/A
Shares Outstanding
31.07M
2.29%
Employees
4.00
N/A
Valuation
2023
Change
P/S Ratio
503.04
N/A
Earnings
2023
Change
Revenue
$210.00K
N/A
Earnings
-$9.93M
N/A
Gross Margin
0.2333
N/A
Operating Margin
-52.43
N/A
Net income margin
-47.29
N/A
logo
Facebook Icon
Twitter Icon
Linkedin Icon
Β© 2024 Topstocks.org